The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
17. August 2026
After 1.5 years of the EU-HTA (launched on 15 January 2025), the results so far are disappointing: Only 22 procedures have been initiated to date, of which 3 have been …
17. August 2026
The medicinal product is identified as “bi-layer engineered skin composed of autologous keratinocytes and allogeneic fibroblasts embedded in an allogeneic plasma matrix”. It is indicated for the treatment of partial …
15. August 2026
Berlin, 15 August 2026
In its first interim arbitration ruling, the arbitration board (Schiedsstelle) considers itself competent in cases where, after a routine practice data collection (anwendungsbegleitende Datenerhebung, AbD) has …
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
